Publications
5491 Results
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9502), abstract 9502; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1512
Neoadjuvant PD-1 Blockade in Patients with Resectable Desmoplastic Melanoma (SWOG 1512)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 12024), poster 270; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Symptom Control and Quality of Life
- Study Number(s)
- S1714
Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9060), poster 48; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1900C
A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic Stk11 Genomic Alterations (SWOG S1900C, LUNG-MAP SUB-STUDY, NCT#04173507)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9004), Abstract #9004; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1800A
Overall survival from a phase II randomized study of ramucirumab pluspembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy—Lung-MAP non-matched sub-studyS1800A
- Journal / Conference
- ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session
- Year
- 2022
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/A051902
A059102: A Randomized Phase II US Intergroup Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 3586), poster 380; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 3553), poster 347; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Gene Expression of Vitamin D (VitD) Pathway Markers and Survival in Patients (Pts) with Metastatic Colorectal Cancer (mCRC): Findings from CALGB/SWOG 80405 (Alliance)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 3580), poster 374; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 1519), poster 113; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Cancer Survivorship
E1Q11: Engendering Reproductive health in Oncologic Survivorship (EROS)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 4020), poster #8; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/EA2142